María Gión
About
María Gión is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, María Gión has authored 70 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in María Gión's work include HER2/EGFR in Cancer Research (23 papers), Cancer Treatment and Pharmacology (19 papers) and Advanced Breast Cancer Therapies (15 papers). María Gión is often cited by papers focused on HER2/EGFR in Cancer Research (23 papers), Cancer Treatment and Pharmacology (19 papers) and Advanced Breast Cancer Therapies (15 papers). María Gión collaborates with scholars based in Spain, United States and Italy. María Gión's co-authors include Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac, Laia Garrigós, Miguel Sampayo-Cordero, Andrea Malfettone, Salvador Blanch, Sofía Braga, Marta Vaz Batista and Manuel Ruíz‐Borrego and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Gastroenterology.
In The Last Decade
María Gión
64 papers receiving 645 citations
Hit Papers
Peers
María Gión
Yunjiang Liu China
Sara Elena Rebuzzi Italy
Mahmoud Ould-Kaci France
Sarah Sammons United States
Maria Bassanelli Italy
Matteo Clavarezza Italy
Minsig Choi United States
Matteo Perrino Italy
Giulia Mazzaschi Italy
Citations per year, relative to María Gión María Gión (= 1×)
peers
Yunjiang Liu
Countries citing papers authored by María Gión
Since
Specialization
Citations
This map shows the geographic impact of María Gión's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Gión with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Gión more than expected).
Fields of papers citing papers by María Gión
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by María Gión. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Gión. The network helps show where María Gión may publish in the future.
Co-authorship network of co-authors of María Gión
This figure shows the co-authorship network connecting the top 25 collaborators of María Gión. A scholar is included among the top collaborators of María Gión based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Gión. María Gión is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
García, José Manuel Pérez, María Gión, Manuel Ruíz‐Borrego, et al.. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 1101–1101.
2.
Llombart‐Cussac, Antonio, José Manuel Pérez-García, María Gión, et al.. (2024). Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC). Cancer Research. 84(9_Supplement). PO1–20.
3.
Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study. Cancer Research. 84(9_Supplement). PS11–5.
4.
Jávega, Beatriz, et al.. (2024). Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review. Frontiers in Immunology. 15. 1513421–1513421.
5.
Antonarelli, Gabriele, et al.. (2024). Moving toward response-adapted trials in oncology. Nature Medicine. 30(12). 3426–3428.
6.
Llombart‐Cussac, Antonio, Fara Brasó‐Maristany, Laia Paré, et al.. (2024). HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial. Clinical Cancer Research. 30(18). 4123–4130.
7.
Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 9(9). 103699–103699.
8.
Cruz, Víctor L., Virginia Souza‐Egipsy, María Gión, et al.. (2023). Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain. International Journal of Molecular Sciences. 24(15). 12031–12031.
9.
Saavedra, Cristina, Alejandro Vallejo, Federico Longo, et al.. (2023). Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors. Cancers. 15(7). 2000–2000.
10.
Saavedra, Cristina, María Gión, Javier Cortés, & Antonio Llombart‐Cussac. (2023). Top advances of the year: Breast cancer. Cancer. 129(12). 1791–1794.
11.
Pérez-García, José Manuel, Marta Vaz Batista, Manuel Ruíz Borrego, et al.. (2023). Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial. Cancer Research. 83(5_Supplement). PD7–2.
12.
Pérez-García, José Manuel, Marta Vaz Batista, Manuel Ruíz‐Borrego, et al.. (2022). Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro-Oncology. 25(1). 157–166.
13.
Pérez-García, José Manuel, Antonio Llombart‐Cussac, María Gión, et al.. (2021). Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. European Journal of Cancer. 148. 382–394.
14.
Batista, Marta Vaz, Antonio Llombart‐Cussac, Manuel Ruíz Borrego, et al.. (2021). 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH. Annals of Oncology. 32. S509–S510.
15.
Quintela-Fandiño, Miguel, Serafín Morales, Luís Manso, et al.. (2019). Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clinical Cancer Research. 26(1). 35–45.
16.
Mezquita, Laura, Mélinda Charrier, Édouard Auclin, et al.. (2017). P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients. Journal of Thoracic Oncology. 12(1). S1315–S1316.
17.
Gión, María, Luigi Mariani, P Stieber, et al.. (2017). Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy). Annals of Oncology. 28. vi81–vi81.
18.
Altman, Douglas G., et al.. (2005). Re: Reporting recommendations for tumor marker prognostic studies (REMARK) - Reply. Oxford University Research Archive (ORA) (University of Oxford).
19.
Dittadi, Ruggero, et al.. (1997). ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method.. PubMed. 17(2B). 1245–7.
20.
Battaglia, Giorgio, et al.. (1994). CEFIXIME FOR THE ERADICATION OF HELICOBACTER-PYLORI. European Journal of Gastroenterology & Hepatology. 6(1). 33–36.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yunjiang Liu Breakdown of academic impact, for papers by Sara Elena Rebuzzi Breakdown of academic impact, for papers by Mahmoud Ould-Kaci Breakdown of academic impact, for papers by Sarah Sammons Breakdown of academic impact, for papers by Maria Bassanelli Breakdown of academic impact, for papers by Matteo Clavarezza Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Matteo Perrino Breakdown of academic impact, for papers by Giulia Mazzaschi